ELANE and neoplasm: Consistently, our immune profiling analyses using both CIBERSORT and xCell demonstrated that high-risk AML patients exhibit a higher proportion of M2 macrophages, further reinforcing the clinical relevance of ELANE in modulating the tumor microenvironment.